Salud financiera de hoja de balance de Addex Therapeutics

Salud financiera controles de criterios 5/6

Addex Therapeutics tiene un patrimonio de los accionistas total de CHF1.1M y una deuda total de CHF0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CHF4.6M y CHF3.5M respectivamente.

Información clave

Ratio deuda-patrimonio

CHF 0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CHF 3.79m
Patrimonio	CHF 12.65m
Total pasivo	CHF 1.05m
Activos totales	CHF 13.70m

Actualizaciones recientes sobre salud financiera

Recent updates

Addex, Indivior expand team up to develop therapies for substance use disorders

Aug 15

Addex stock falls 11% amid $4.2M equity financing with Armistice

Jul 22

Addex Therapeutics CEO Tim Dyer - Emerging Drugs For Central Nervous System (Video)

Oct 21

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CHF4.7M) de ADXN superan a sus pasivos a corto plazo (CHF943.0K).

Pasivo a largo plazo: Los activos a corto plazo de ADXN (CHF4.7M) superan a sus pasivos a largo plazo (CHF102.9K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ADXN está libre de deudas.

Reducción de la deuda: ADXN no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ADXN tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: ADXN dispone de suficiente cash runway para 1.4 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 16.3% cada año.

Salud financiera de hoja de balance de Addex Therapeutics

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Addex Regains Nasdaq Listing Compliance

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Addex Regains Nasdaq Listing Compliance

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Recent updates

Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Addex Therapeutics Ltd Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium

Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024

Addex Therapeutics Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024

Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders

Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million.

Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million.

Addex Therapeutics Ltd to Report Q3, 2024 Results on Nov 11, 2024

Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Addex Regains Nasdaq Listing Compliance

Addex Therapeutics Announces Data Published in Brain

Addex Therapeutics Ltd announced that it has received CHF 2.7 million in funding from Indivior PLC

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Addex Therapeutics Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

Addex Regains Nasdaq Listing Compliance

Addex Therapeutics Ltd to Report Fiscal Year 2022 Results on Mar 13, 2023

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Addex, Indivior expand team up to develop therapies for substance use disorders

Addex Therapeutics Ltd announced that it has received funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive funding from Armistice Capital LLC

Addex stock falls 11% amid $4.2M equity financing with Armistice

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate

Addex Therapeutics Ltd Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Addex Therapeutics Ltd Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Addex Therapeutics Ltd Expands Pipeline with Selective M4 Positive Allosteric Modulator Program

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Addex Therapeutics Ltd announced that it has received CHF 5.427937 million in funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive CHF 5.427937 million in funding from Armistice Capital LLC

Addex Therapeutics CEO Tim Dyer - Emerging Drugs For Central Nervous System (Video)

Addex Therapeutics Ltd Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

Addex Therapeutics Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

Addex, Janssen initiate Phase 2 study of ADX71149 for epilepsy

Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia

Addex Therapeutics reports Q1 results

Addex Therapeutics Ltd to Report Q1, 2021 Results on May 03, 2021

Enamine Ltd. Extends Collaboration with Addex Therapeutics Ltd

Addex Therapeutics Announces New Treatment Option for Severe Alcohol Use Disorder

Addex Therapeutics Ltd to Report Fiscal Year 2020 Results on Mar 08, 2021

Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy

Addex drops 23% after pricing share offering

Addex Therapeutics files to sell $10M of ADS

Addex Therapeutics reports Q3 results

Addex Therapeutics Ltd to Report Q3, 2020 Results on Nov 03, 2020

Addex Therapeutics Ltd to Report First Half, 2020 Results on Aug 12, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera